Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants - (BMJ)
    Topical Cream Effective Against Cetuximab-Induced Acne-Like Rash: Presented at ESMO-GI - (DGDispatch)
    Endocrine Society Responds to Insulin Glargine Studies With Recommendations - (DGNews)
    Two Bevacizumab-Based Combination Regimens Equally Effective in Patients With Metastatic Colorectal Cancer: Presented at ESMO-GI - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Biologics in Crohn's Disease: Treating Early, Treating Long-Term
    • Urinalysis: A Guide for Pharmacists
      Clinical Management of Nutrition in Hospitalized Patients: Improving Safety and Patient Outcomes
      Advances in the Management of Postoperative Ileus: Reducing the Clinical and Economic Burden
      The Challenge of Type 2 Diabetes: Emerging Options for Improving Glycemic Control

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
        Acute Abdominal Pain in a Patient Receiving Enoxaparin
        Fatal Pneumonitis After Treatment with Docetaxel and Trastuzumab
        Cardiogenic Shock Caused by Disulfiram
        Clopidogrel Resistance "Live" - The Risk of Stent Thrombosis Should Be Evaluated Before Procedures

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        FDA Issues Warning On Phenylpropanolamine In Many Cold, Weight Loss Products

        WASHINGTON, DC -- November 7, 2000 -- The FDA is taking steps to remove phenylpropanolamine from all drug products and has requested that all drug companies discontinue marketing products containing phenylpropanolamine.

        FDA has issued a public health advisory concerning the risk of hemorrhagic stroke, or bleeding into the brain, associated with phenylpropanolamine hydrochloride.

        Phenylpropanolamine is an ingredient used in many over-the-counter (OTC) and prescription cough and cold medications as a decongestant and in OTC weight loss products.

        Adverse events reported with these products led to concerns that this ingredient might increase the risk of hemorrhagic strokes. Manufacturers of products containing phenylpropanolamine worked with FDA to plan a research program to clarify whether any increase in risk exists. Scientists at Yale University School of Medicine conducted the study in which the researchers found an association between phenylpropanolamine use and stroke in women. The increased risk of hemorrhagic stroke was detected among women using the drug for weight control, and for nasal decongestion, in the 3 days after starting use of the medication. Men may also be at risk.

        The Nonprescription Drugs Advisory Committee met on October 19 to discuss safety issues related to phenylpropanolamine use. The committee reviewed Yale's Hemorrhagic Stroke Project results and concluded that phenylpropanolamine cannot be considered to be safe for continued use.FDA believes that although the risk of hemorrhagic stroke is very low, even with phenylpropanolamine use, the conditions for which these products are used do not appear to warrant an increased risk of this serious event from using this drug. We advise consumers to discuss alternative over-the-counter and prescription products with their health care providers or pharmacists.

        Information about the history of phenylpropanolamine, the Public Health Advisory, and the stroke study results can be found on the FDA website at: www.fda.gov/cder/drug/infopage/ppa/default.htm.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send